Navigation Links
Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Date:4/26/2012

he complete data set at an upcoming scientific meeting."

Dr. Michael Davidson, Co-Founder and Chief Medical Officer of Omthera, stated, "In addition to the triglyceride lowering benefit, we were pleased to observe from these top-line results a meaningful decrease of 8% in non-HDL-cholesterol in both the 2 and 4 gram dose groups.  We believe these data will be important for Epanova in light of the growing reliance of the medical community (Journal of the American Medical Association, March 28, 2012 – Vol 307, No 12) on non-HDL-cholesterol as the more accurate arbiter of the risk for cardiovascular disease, especially in patients with hypertriglyceridemia. We have recently completed enrollment and randomization in ESPRIT, our 647 patient statin combination study.   The primary objective of ESPRIT is to evaluate the efficacy of adding Epanova (2 gram or 4 gram daily) to statin monotherapy for lowering non-HDL-cholesterol.  We look forward to the results from this study, expected in July 2012, to further validate the progression of Epanova as a best-in-class therapy for the treatment of patients with mixed dyslipidemia."

About Epanova™

Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera has developed a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega-3 products currently available.  Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's disease patients with normal triglyceride levels for ≥52 weeks, approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability pr
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
2. Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
3. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
4. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
5. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
6. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
7. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
8. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
9. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
10. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...   Easy Breathe , the fastest growing online sleep ... " - has received more than 4.5 million unique page views ... thrilled that so many people are finding our blog and reading ... "We,re committed to making sleep apnea more widely known and hope ... sleep apnea news , troubleshooting advice , and ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... new market research report is available in its ... Electronic Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... fast-changing market for electronic medical records (EMR) for ... a comprehensive report of our findings. Our report ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of ... has elected Thomas J. Dietz, Ph.D., as the company,s ... Holdings, LLC, a diversified financial-holdings and services company.   ... then CEO and a director of Pacific Growth Equities, ...
... Reportlinker.com announces that a new market ... Medical Imaging Markets: Contrast ... The application and versatility of ... in significance as the population ages and ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:8/20/2014)... The Board of Directors of top ... is pleased to announce the expansion of its ... and the surrounding region. In support of this ... AIA has relocated to the firm’s office in Shanghai, ... and design and to better support regional clients. ...
(Date:8/20/2014)... the most persistent and deadliest infectious diseases in the ... , Scientists who study tuberculosis have long debated its ... humans in Africa to seals and sea lions that ... to Native people there before Europeans landed on the ... as a Source of New World Human Tuberculosis," was ...
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... 20, 2014 As concerns regarding the ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery continue ... Senators from New York are urging the U.S. Food ... the devices. In a letter dated August 19th, Sens. ... the agency to seriously consider the testimony given during ...
(Date:8/20/2014)... NY (August 20, 2014) Research from Columbia University ... role in stomach cancer growth and that blocking nerve ... effective treatment for the disease. The study was conducted ... collaboration with Duan Chen, MD, PhD, in Norway and ... Medicine . , "Scientists have long observed that human ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... with current devices , , MONDAY, Jan. 21 (HealthDay News) ... for overcoming the major problems with these tubes that ... Italian researchers report. , The new stent is not ... use, but with a special polymer designed to prevent ...
... in 2007, KNOXVILLE, Tenn., Jan. 21 ... clinical outsourcing, announced today,that it has initiated ... December 2007 and January 2008. These contracts ... medicine programs in seven,states., TeamHealth will ...
... WASHINGTON, Jan. 21 Senator Sam Brownback,and Rep. ... for Life, on,Tuesday, January 22, 2008. The conference ... College Professor Hadley P.,Arkes, Eric Scheidler, Michael Illions, ... live from Family Research Council,s headquarters., Senator ...
... DIEGO, Jan. 21 AMN Healthcare Services,Inc. (NYSE: ... United,States, will host its quarterly conference call to discuss ... 2008, at 5:00 p.m. Eastern,Time. The company expects to ... 2008 at approximately 4:00 p.m. Eastern Time., A ...
... Biosciences,(Nasdaq: MATK ) announced today that life,sDHA(TM), its ... heart health, is now available to,Australian consumers in Pocket ... is the largest juice and smoothie chain in the,Southern ... Pocket Rocket Juice provides,more than 100 percent of Australia,s ...
... kick butts, SAN DIEGO, Jan. 21 RealAge.com, ... a new program to guide and,support nicotine-free wannabes as ... Stop Smoking Center launched today. The center is packed,with ... MD, a,founder of RealAge and coauthor of YOU: Staying ...
Cached Medicine News:Health News:'Drug-Free' Stent Coating Shows Promise 2Health News:TeamHealth Announces Eight New Clinical Outsourcing Contracts 2Health News:Senator Sam Brownback and Rep. Chris Smith to Speak at Blogs for Life 2Health News:AMN Healthcare Services to Host 2007 Fourth Quarter & Year End Earnings Conference Call on Tuesday, February 26, 2008 2Health News:Pocket Rocket Juice from Australia's Boost Juice Features 700 mg of Martek's life'sDHA(TM) 2Health News:Pocket Rocket Juice from Australia's Boost Juice Features 700 mg of Martek's life'sDHA(TM) 3Health News:RealAge Challenges and Cheers Smoke-Free Wannabes in 2008 2
... enzyme linked immunosorbent assay ... and semiquantitation of anti-glomerular ... in human serum. The ... can be used as ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
Rheumatoid factor screening...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) IgA isotype in human serum....
Medicine Products: